Press Release on Financial Results
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 01 Aug 2026, 05:04 PM IST · BSE ID: 59543db7-a848-422c-8c08-3444eb6a9eaf
View Original BSE Filing (PDF)
💡
In Simple Terms
The pharmaceutical company's revenue increased by 6% to ₹207.0 crore in the latest quarter, driven by strong drug ingredient sales.
🤖 AI Summary
- SMS Pharmaceuticals reported Q1 FY27 revenue from operations of ₹207.0 crore, a 6% YoY increase.
- Gross profit for Q1 FY27 was ₹74.9 crore, with gross margin at 36%, reflecting a 217 bps YoY expansion.
- PAT increased 8% YoY to ₹20.20 crore in Q1 FY27, maintaining a PAT margin of 10%.
- Company completed 4 DMF/CEP filings in Q1 FY27 and expects to complete 10 filings by FY27 end.
- Board approved infusion of up to ₹50 crore as a loan into subsidiary SMS Peptides Private Limited.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1FY27)
207.0 ₹ Cr
6%
Gross profit (Q1FY27)
74.9 ₹ Cr
12%
Gross profit margin (Q1FY27)
36%
217bps
EBITDA (Q1FY27)
40.95 ₹ Cr
4%
EBITDA margin (Q1FY27)
20%
-30bps
PAT (Q1FY27)
20.20 ₹ Cr
8%
PAT margin (Q1FY27)
10%
21bps
Capex program total outlay
280 ₹ crore
Capex completed
120 ₹ crore
Investment in SMS Peptides Pvt Ltd (loan)
50 ₹ crore
DMF/CEP filings completed (Q1FY27)
4
🏢 How This Affects the Company
Revenue growth was driven by diversified expansion across high-value APIs, with the ARV portfolio showing strong market share gains and Ibuprofen sustaining healthy demand. Completion of 4 DMF/CEP filings and an R&D team strength of 200 supports future product pipeline development.
Gross profit margin expanded 217 bps YoY to 36%, benefiting from backward integration and improved product mix, contributing to an 8% YoY increase in PAT to ₹20.20 crore. An approved ₹50 crore loan to a subsidiary indicates capital allocation towards peptide CDMO platform expansion.
The ongoing ₹280 crore capex program, with ₹120 crore completed, will support commercialization of new niche and high-value molecules, enhancing manufacturing capabilities. Increased R&D team strength to 200 members directly supports development pipeline expansion.
EBITDA margins were impacted by annual employee increments and elevated freight costs due to geopolitical situations in West Asia. These factors present temporary cost pressures on profitability, although the company expects them to ease.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results press release.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with PAT increasing 8% YoY to ₹20.20 crore and EPS at ₹2.23 in Q1 FY27.
🔍
Management Signal
Management signals continued investment in growth through a ₹280 crore capex program and a ₹50 crore loan to a subsidiary for peptide platform development, aiming for sustained 20% EBITDA margins.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor continued revenue growth and margin performance.
Progress of ₹280 crore capex program — confirm completion by FY27.
Achievement of FY27 target of 10 DMF/CEP filings — check updates on new product pipeline.
MEDIUM RISK
EBITDA margins were impacted by geopolitical freight costs and employee increments, indicating external and internal cost pressures.
💡 Investor Takeaway
SMS Pharmaceuticals reported Q1 FY27 revenue from operations of ₹207.0 crore, up 6% YoY, with PAT increasing 8% YoY to ₹20.20 crore. Gross profit margin expanded 217 bps YoY to 36%.
⚖️ Strengths & Concerns
✅ Positives
- Gross profit margin expanded 217 bps YoY to 36% in Q1 FY27, reflecting structural improvements from backward integration and product mix.
- Revenue from operations grew 6% YoY to ₹207.0 crore, driven by diversified growth across high-value APIs and strong ARV portfolio performance.
⚠️ Concerns
- EPS decreased 3% YoY to ₹2.23 in Q1 FY27, despite a PAT increase, and dropped 38% QoQ from ₹3.58.
- EBITDA margin saw a marginal decline of 30 bps YoY to 20% in Q1 FY27, impacted by employee increments and elevated freight costs.
📅 Company Track Record
SMS Pharmaceuticals scheduled an August 1, 2026 board meeting for Q1 FY27 results, as previously informed on July 25, 2026. This filing confirms the announcement of those results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was SMS Pharmaceuticals' revenue from operations in Q1 FY27?
SMS Pharmaceuticals reported revenue from operations of ₹207.0 crore in Q1 FY27, which is a 6% increase compared to Q1 FY26.
What was SMS Pharmaceuticals' Net Profit (PAT) for the quarter ended June 30, 2026?
Net Profit (PAT) for SMS Pharmaceuticals in Q1 FY27 was ₹20.20 crore, representing an 8% increase year-over-year.
What is the status of SMS Pharmaceuticals' capex program?
SMS Pharmaceuticals' ₹280 crore capex program is progressing, with ₹120 crore completed and the remaining ₹160 crore expected to be completed by FY27.
How much capital did SMS Pharmaceuticals' Board approve for its subsidiary SMS Peptides Private Limited?
The Board approved an infusion of up to ₹50 crore, as a loan, into its subsidiary SMS Peptides Private Limited.
How many DMF/CEP filings did SMS Pharmaceuticals complete in Q1 FY27?
SMS Pharmaceuticals completed 4 DMF/CEP filings during Q1 FY27 and remains on track to meet its FY27 target of 10 DMF/CEP filings.
Questions based on this BSE filing only. For information purposes.